Brief: AB Science Receives NOD From Health Canada For Masitinib
13/12/2022 17:18
Dec 13 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF DEFICIENCY (NOD) FROM HEALTH
CANADA FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL
SCLEROSIS (ALS)
* AB SCIENCE WILL LIAISE WITH HEALTH CANADA TO ADDRESS
DEFICIENCIES, WITH INTENTION TO RESUME PROCESS WITHIN ALLOCATED
TIMEFRAME
Source text for Eikon: ID:nGNX7wf87V
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease